^
    Back
    Association details:
    Biomarker:BIRC5 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Asian Pac J Cancer Prev
    Title:

    Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer

    Published date:
    09/29/2023
    Excerpt:
    Patients with low TUBB3 expression and high RRM1 and survivin expression had higher response rates than those with low RRM1 and survivin expression and high TUBB3 expression in the Car/Pac regimen.
    DOI:
    10.31557/APJCP.2023.24.9.3003